RATIONALE: Obstructive sleep apnea (OSA) is a risk factor for cardiovascular disease. We hypothesized that patients with OSA and no cardiovascular disease have oxidant-related microcirculatory endothelial dysfunction. OBJECTIVES: To evaluate the microcirculation in OSA. METHODS: This study included seven patients with OSA and seven age- and weight-matched control subjects (mean age, 38 yr; mean body mass index, 32.5 kg/m²). All participants were free of cardiovascular risk factors. Participants received measurement of brachial artery flow-mediated dilation and forearm subcutaneous biopsy. Patients underwent repeated tests 12 weeks after treatment. Microcirculatory endothelial cells were isolated, and immunohistochemistry staining for peroxynitrite in the microcirculation was performed. MEASUREMENTS AND MAIN RESULTS: Flow-mediated dilation was lower in patients than in control subjects at baseline (mean ± SEM: 5.7 ± 0.5 vs. 9.5 ± 0.6; P = 0.02) and increased after treatment (5.7-7.3; change, 1.7 ± 0.6; P = 0.04). Microcirculatory peroxynitrite deposit was higher in patients compared with control subjects (44.0 ± 1.6 vs. 21.8 ± 1.9 stain density units; P < 0.001) and decreased after treatment from 44.0 to 30.5 stain density units (change, -13.5 ± 2.9; P = 0.009). In patients, transcription of endothelial nitric oxide synthase decreased from 5.2 to -1.3 after treatment (change, 6.5 ± 2.5; P = 0.05), and transcription of superoxide dismutase1 decreased from -4.0 to -12.3 after treatment (change, -8.3 ± 2.1; P = 0.01). These changes persisted after adjustment for weight and underlying severity of OSA. CONCLUSIONS: This is the first direct evaluation of the microcirculation in OSA. Patients with OSA with low cardiovascular risk status had increased oxidant production in the microcirculation and endothelial dysfunction, both of which improved with treatment. Endothelial nitric oxide synthase transcription decreased with treatment.
RATIONALE: Obstructive sleep apnea (OSA) is a risk factor for cardiovascular disease. We hypothesized that patients with OSA and no cardiovascular disease have oxidant-related microcirculatory endothelial dysfunction. OBJECTIVES: To evaluate the microcirculation in OSA. METHODS: This study included seven patients with OSA and seven age- and weight-matched control subjects (mean age, 38 yr; mean body mass index, 32.5 kg/m²). All participants were free of cardiovascular risk factors. Participants received measurement of brachial artery flow-mediated dilation and forearm subcutaneous biopsy. Patients underwent repeated tests 12 weeks after treatment. Microcirculatory endothelial cells were isolated, and immunohistochemistry staining for peroxynitrite in the microcirculation was performed. MEASUREMENTS AND MAIN RESULTS: Flow-mediated dilation was lower in patients than in control subjects at baseline (mean ± SEM: 5.7 ± 0.5 vs. 9.5 ± 0.6; P = 0.02) and increased after treatment (5.7-7.3; change, 1.7 ± 0.6; P = 0.04). Microcirculatory peroxynitrite deposit was higher in patients compared with control subjects (44.0 ± 1.6 vs. 21.8 ± 1.9 stain density units; P < 0.001) and decreased after treatment from 44.0 to 30.5 stain density units (change, -13.5 ± 2.9; P = 0.009). In patients, transcription of endothelial nitric oxide synthase decreased from 5.2 to -1.3 after treatment (change, 6.5 ± 2.5; P = 0.05), and transcription of superoxide dismutase1 decreased from -4.0 to -12.3 after treatment (change, -8.3 ± 2.1; P = 0.01). These changes persisted after adjustment for weight and underlying severity of OSA. CONCLUSIONS: This is the first direct evaluation of the microcirculation in OSA. Patients with OSA with low cardiovascular risk status had increased oxidant production in the microcirculation and endothelial dysfunction, both of which improved with treatment. Endothelial nitric oxide synthase transcription decreased with treatment.
Authors: John Buterbaugh; Charles Wynstra; Natalie Provencio; Daniel Combs; Michael Gilbert; Sairam Parthasarathy Journal: Sleep Date: 2015-02-01 Impact factor: 5.849
Authors: Rami N Khayat; Saradhadevi Varadharaj; Kyle Porter; Angela Sow; David Jarjoura; Mikhail A Gavrilin; Jay L Zweier Journal: Am J Hypertens Date: 2018-02-09 Impact factor: 2.689
Authors: Saradhadevi Varadharaj; Kyle Porter; Adam Pleister; Jacob Wannemacher; Angela Sow; David Jarjoura; Jay L Zweier; Rami N Khayat Journal: Respir Physiol Neurobiol Date: 2014-12-19 Impact factor: 1.931
Authors: Henry Blomster; Tomi Laitinen; Tiina Lyyra-Laitinen; Esko Vanninen; Helena Gylling; Markku Peltonen; Tarja Martikainen; Johanna Sahlman; Jouko Kokkarinen; Jukka Randell; Grigori Smirnov; Juha Seppä; Henri Tuomilehto Journal: Sleep Breath Date: 2013-06-04 Impact factor: 2.816
Authors: Mako Nagayoshi; Pamela L Lutsey; David Benkeser; Christina L Wassel; Aaron R Folsom; Eyal Shahar; Hiroyasu Iso; Matthew A Allison; Michael H Criqui; Susan Redline Journal: Atherosclerosis Date: 2016-06-25 Impact factor: 5.162